About ICON Public Limited Company
https://www.iconplc.comICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
CEO
Barry Balfe
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2008-08-13 | Forward | 2:1 |
| 2006-10-24 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 94
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Rothschild & Co
Buy
UBS
Buy
Truist Securities
Buy
Baird
Outperform
Evercore ISI Group
Outperform
Mizuho
Outperform
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
METATRON CAPITAL SICAV PLC
Shares:81.4M
Value:$15.04B
ARTISAN PARTNERS LIMITED PARTNERSHIP
Shares:7.07M
Value:$1.31B
WELLINGTON MANAGEMENT GROUP LLP
Shares:4.64M
Value:$856.8M
Summary
Showing Top 3 of 691
About ICON Public Limited Company
https://www.iconplc.comICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.04B ▲ | $197.05M ▼ | $2.35M ▼ | 0.12% ▼ | $0.03 ▼ | $186.84M ▼ |
| Q2-2025 | $2.02B ▲ | $352.39M ▲ | $182.97M ▲ | 9.07% ▲ | $2.31 ▲ | $308.98M ▼ |
| Q1-2025 | $2B ▼ | $339.09M ▲ | $154.15M ▼ | 7.7% ▼ | $1.91 ▼ | $317.32M ▼ |
| Q4-2024 | $2.04B ▲ | $302.34M ▼ | $260M ▲ | 12.74% ▲ | $3.18 ▲ | $365.65M ▼ |
| Q3-2024 | $2.03B | $305.98M | $197.13M | 9.71% | $2.38 | $380.9M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $468.89M ▲ | $16.51B ▼ | $7.17B ▲ | $9.33B ▼ |
| Q2-2025 | $390.4M ▼ | $16.6B ▼ | $7.05B ▼ | $9.56B ▲ |
| Q1-2025 | $526.7M ▼ | $16.72B ▼ | $7.22B ▼ | $9.5B ▼ |
| Q4-2024 | $538.78M ▼ | $16.88B ▼ | $7.35B ▼ | $9.52B ▼ |
| Q3-2024 | $695.51M | $17.21B | $7.44B | $9.77B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.35M ▼ | $408.51M ▲ | $-59.24M ▼ | $-272.36M ▲ | $78.49M ▲ | $351.89M ▲ |
| Q2-2025 | $182.97M ▲ | $162.19M ▼ | $-41.12M ▼ | $-275.49M ▼ | $-136.3M ▼ | $127.55M ▼ |
| Q1-2025 | $154.15M ▼ | $268.24M ▼ | $-37.28M ▲ | $-252.83M ▲ | $-12.09M ▲ | $239.33M ▼ |
| Q4-2024 | $260M ▲ | $338.31M ▼ | $-68.88M ▲ | $-403.96M ▼ | $-156.72M ▼ | $277.03M ▼ |
| Q3-2024 | $197.13M | $402.67M | $-124.34M | $-97.78M | $188.95M | $359.34M |
Revenue by Products
| Product | Q4-2011 | Q3-2012 | Q4-2012 |
|---|---|---|---|
 Central Laboratory | $20.00M ▲ | $20.00M ▲ | $60.00M ▲ |
 Clinical Research | $220.00M ▲ | $260.00M ▲ | $770.00M ▲ |
Revenue by Geography
| Region | Q4-2022 | Q4-2023 | Q2-2023 | Q1-2023 |
|---|---|---|---|---|
 IRELAND | $590.00M ▲ | $1.27Bn ▲ | $590.00M ▼ | $510.00M ▼ |
 Rest Of Europe | $340.00M ▲ | $790.00M ▲ | $370.00M ▼ | $410.00M ▲ |
 Rest of World | $0 ▲ | $0 ▲ | $210.00M ▲ | $210.00M ▲ |
 UNITED STATES | $810.00M ▲ | $1.59Bn ▲ | $850.00M ▼ | $840.00M ▼ |
CEO
Barry Balfe
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2008-08-13 | Forward | 2:1 |
| 2006-10-24 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 94
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Rothschild & Co
Buy
UBS
Buy
Truist Securities
Buy
Baird
Outperform
Evercore ISI Group
Outperform
Mizuho
Outperform
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
METATRON CAPITAL SICAV PLC
Shares:81.4M
Value:$15.04B
ARTISAN PARTNERS LIMITED PARTNERSHIP
Shares:7.07M
Value:$1.31B
WELLINGTON MANAGEMENT GROUP LLP
Shares:4.64M
Value:$856.8M
Summary
Showing Top 3 of 691